Investment Analysts’ Recent Ratings Changes for Tempus AI (TEM)

A number of firms have modified their ratings and price targets on shares of Tempus AI (NASDAQ: TEM) recently:

• 8/4/2026 – Tempus AI had its price target lowered by Piper Sandler from $58.00 to $56.00. They now have a “neutral” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by BTIG Research from $80.00 to $70.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by HC Wainwright from $64.00 to $56.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by Stifel Nicolaus from $60.00 to $50.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 7/25/2026 – Tempus AI was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/24/2026 – Tempus AI had its “buy” rating reaffirmed by HC Wainwright.
• 7/20/2026 – Tempus AI was downgraded by Lake Street Capital to “hold”.
• 7/20/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 7/16/2026 – Tempus AI had its price target raised by Guggenheim from $60.00 to $65.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Tempus AI had its “buy” rating reaffirmed by TD Cowen.
• 7/4/2026 – Tempus AI was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/30/2026 – Tempus AI was upgraded by Freedom Capital to “hold”.
• 6/17/2026 – Tempus AI had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the sale, the chief executive officer directly owned 200,000 shares of the company’s stock, valued at approximately $8,412,000. This represents a 55.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 723,981 shares of company stock valued at $34,879,442 over the last 90 days. 24.26% of the stock is currently owned by company insiders.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.